U.S. Supreme Court Declines to Hear CareDx's Appeal Against Natera
The U.S. Supreme Court has declined to hear an appeal from CareDx in its false-advertising dispute with diagnostics company Natera, Inc. (NASDAQ:NTRA). This decision upholds previous rulings that denied damages for claims involving kidney transplant tests and confirms the jury's finding of false advertising.
Topics: diagnostics healthcare intellectual property supreme court